Apricus Biosciences Inc.’s (APRI) resubmitted New Drug Application for Vitaros awaits the FDA's final word, which is expected on February 17, 2018.Vitaros is a novel, on-demand topical cream for the treatment of erectile dysfunction, in-licensed from Warner Chilcott Co. Inc., now a subsidiary of Allergan plc. (AGN).It is approved in Canada, Mexico, and certain countries in Europe, Latin America and the Middle East.This is Vitaros’ second go-around with the FDA. It was turned down by the U.S. regulatory agency in July 2008, with questions being raised about the results of a transgenic mouse carcinogenicity study, which were completed in 2002.Will Vitaros make it to the finish line this time? APRI closed Thursday’s (Jan.25) trading at $2.32, down 6.16%.